Categories: News

Pipeline Update on gRAD Tests

December 31, 2021
News release

Pipeline Update on gRAD Tests

BioPorto A/S (BioPorto) is supporting Rigshospitalet (RH), Copenhagen, with quantitative thrombomodulin tests based on its generic Rapid Assay Device (gRAD) technology. RH is investigating the potential for thrombomodulin blood levels to be used as a marker in patients with sepsis to indicate who could benefit from treatment with the drug prostacyclin. RH is currently summarizing findings from its feasibility study and plans to publish the results after completing its assessment.

BioPorto is also using the gRAD platform in a feasibility study to detect SARS-CoV-2, the virus that causes COVID-19. As results from the previous data collection were not conclusive, BioPorto is extending the feasibility study into 2022, including expanding the study to include the omicron SARS-CoV-2 variant.

For further information, please contact:

Tim Eriksen, Investor Relations
+45 6168 7779, e-mail: investor@bioporto.com

About BioPorto
BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment

Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

7 hours ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

7 hours ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

1 day ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

1 day ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

1 day ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

1 day ago